Novelos' lung-cancer treatment NOV-002 gets fast-track status

By Lisa Kerner

Charlotte, N.C., Aug. 7 - Novelos Therapeutics, Inc. said the Food and Drug Administration has granted fast-track designation to its small molecule drug, NOV-002, for use in combination with first-line chemotherapy for the treatment of advanced non-small cell lung cancer.

The fast-track program accelerates the review process for new drugs that have the potential to address serious and unmet medical conditions, according to a company news release.

Under the rolling review process, the FDA will review subsections of Novelos' NOV-002 New Drug Application as they become available.

In 2006, approximately 175,000 Americans will be diagnosed with lung cancer, the leading cause of cancer death in the United States, according to Novelos and the American Cancer Society.

Located in Newton, Mass., Novelos is a biotechnology company that develops therapeutics to treat cancer and hepatitis.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.